Abstract 5054
Background
PD-1/PD-L1 antibody can be effective on less than 30-40% of solid tumors. It is urgent to find new targets or combining therapies to broaden the patient populations so that more cancer patients can be successfully treated by PD-1/PD-L1 checkpoint blockade inhibition. Recent studies supported that targeting Wnt/b-Catenin signaling would increase anti-cancer immune evasion response through regulation of immune cell infiltration within the tumor microenvironment. Several lines of evidence have revealed that the family members of R-spondins (RSPOs) can mediate with Lgr4 or Lgr5 proteins/Frizzled/LRP receptor complexes as an independent (noncanonical) control of the Wnt pathway. Multiple cancer types were found to bear aberrant RSPO3/Wnt signaling.
Methods
In this study, we have identified an anti-RSPO3 antibody (DBPR117) as shown in a variety of assays including the lignad binding assays, in vitro bioassays, in vivo PDX (patient-derive xenograft), and mouse syngeneic models. DBPR117 is capable of binding and neutralizing human as well as murine RSPO3 in cell culture.
Results
Dependent on the cancer types, effective tumor growth inhibition in vivo can be achieved by administration by DBPR117 alone, or in combination with an anti-PD1 antibody. The interplays of RSPO3 and PD1 on tumor growth and metastases will be elucidated and discussed. How the findings in the laboratory may be translated into clinics will also be presented.
Conclusions
Additional studies are warranted to evaluate how DBPR117, a novel anti-RSPO3 humanized antibody, may be translated into clinical applications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Health and Welfare.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract